The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...

Furthermore, Scholar Rock appointed Rebecca McLeod as Chief Brand Officer and U.S. General Manager to lead the U.S. commercial launch of apitegromab. The company continues to prepare for the potential ...

David Hallal, Scholar Rock CEO, joins 'Fast Money' to talk its recent drug study results that found its drug taken in combination with Zepbound helped prevent muscle loss.

View the latest Scholar Rock Holding Corp. (SRRK) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I think SRRK stock could be a Buy.

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and ...

Any forward-looking statements represent Scholar Rock’s views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release ...

FLAT ROCK, MI — Flat Rock Community Schools announced the top 10 graduates in the Flat Rock High School Class of 2025. The Monroe News showcases the top scholars in each Monroe County school ...

Flat Rock Community Schools announced the top 10 graduating seniors of Flat Rock High School's Class of 2025. The Monroe News highlighted these students' achievements and post-graduation plans.